Quick Answer
CytomX Therapeutics, Inc. reported Operating Income Loss of -$22.36 million for the year ending 2025.
- CytomX Therapeutics, Inc. showed a decrease of -189.5% in Operating Income Loss from 2024 to 2025.
- This data is from CytomX Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), CytomX Therapeutics, Inc.'s Operating Income Loss has declined by 49.5%.
- Historical annual values: Fiscal year 2025: -$22.36 million | Fiscal year 2024: $25.00 million | Fiscal year 2023: -$6.48 million | Fiscal year 2022: -$101.34 million | Fiscal year 2021: -$116.04 million | Fiscal year 2020: -$48.61 million | Fiscal year 2019: -$110.90 million | Fiscal year 2018: -$77.87 million | Fiscal year 2017: -$46.26 million | Fiscal year 2016: -$59.59 million | Fiscal year 2015: -$33.20 million | Fiscal year 2014: -$29.77 million | Fiscal year 2013: -$14.96 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: